ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
67 301,29
0,54%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Flexion Therapeutics Inc (FLXN)

  7. Flexion Therapeutics Inc (FLXN) Actualités

FLXN

Flexion Therapeutics (FLXN)

Flexion Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:FLXN
DateHeureSourceTitreSymboleSociété
26/11/202112h07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:FLXNFlexion Therapeutics Inc
24/11/202112h24Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202116h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202115h29Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202115h27Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202115h12Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202115h02Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:FLXNFlexion Therapeutics Inc
19/11/202114h40GlobeNewswire Inc.Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain ManagementNASDAQ:FLXNFlexion Therapeutics Inc
22/10/202112h49Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:FLXNFlexion Therapeutics Inc
22/10/202112h07Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:FLXNFlexion Therapeutics Inc
12/10/202122h17Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:FLXNFlexion Therapeutics Inc
12/10/202112h08Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:FLXNFlexion Therapeutics Inc
11/10/202122h26PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.NASDAQ:FLXNFlexion Therapeutics Inc
11/10/202113h00GlobeNewswire Inc.Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain ManagementNASDAQ:FLXNFlexion Therapeutics Inc
01/10/202122h30GlobeNewswire Inc.Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FLXNFlexion Therapeutics Inc
08/09/202122h30GlobeNewswire Inc.Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceNASDAQ:FLXNFlexion Therapeutics Inc
03/09/202115h00GlobeNewswire Inc.Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare ConferenceNASDAQ:FLXNFlexion Therapeutics Inc
02/09/202113h30GlobeNewswire Inc.Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the KneeNASDAQ:FLXNFlexion Therapeutics Inc
25/08/202113h30GlobeNewswire Inc.Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative PainNASDAQ:FLXNFlexion Therapeutics Inc
09/08/202122h30GlobeNewswire Inc.Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)NASDAQ:FLXNFlexion Therapeutics Inc
04/08/202122h10Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:FLXNFlexion Therapeutics Inc
04/08/202122h03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FLXNFlexion Therapeutics Inc
04/08/202122h01GlobeNewswire Inc.Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business HighlightsNASDAQ:FLXNFlexion Therapeutics Inc
29/07/202122h15GlobeNewswire Inc.Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021NASDAQ:FLXNFlexion Therapeutics Inc
12/07/202122h30GlobeNewswire Inc.Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of DirectorsNASDAQ:FLXNFlexion Therapeutics Inc
12/07/202122h04Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:FLXNFlexion Therapeutics Inc
02/07/202122h30GlobeNewswire Inc.Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FLXNFlexion Therapeutics Inc
14/06/202122h30GlobeNewswire Inc.Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation ConferenceNASDAQ:FLXNFlexion Therapeutics Inc
09/06/202122h15GlobeNewswire Inc.Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical OfficerNASDAQ:FLXNFlexion Therapeutics Inc
02/06/202122h30GlobeNewswire Inc.Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual ConferenceNASDAQ:FLXNFlexion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FLXN

Dernières Valeurs Consultées

NASDAQ
ABAELXX
Bank of Montreal Capped ...
BIT
F19025
Vontobel Financial Produ...
USOTC
CPRGF
CPN Retail Growth Leaseh... (PK)
NASDAQ
LOUD
Loudeye
ASX
BD1
Bard1 Life Sciences
HUOB
UTUSDT
Universal Token
LSE
5OGU
Ossiam Sb C Gsv
COIN
TRDSEUR
LSE
CICG
GDAX
BADGEREUR
Badger
AQEU
ASIP
Amundi MSCI China ESG Le...
ASX
XCLWAM
Australian Commonwealth ...
USOTC
YZZKF
Yamazaki Baking (PK)
COIN
XMYUST
Myriad
USOTC
OVSPW
Overseas Shipholding Gro... (CE)
AMEX
EJAN
Innovator Emerging Marke...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés